$1.95
0.52% yesterday
Nasdaq, Aug 25, 10:00 pm CET
ISIN
IL0011429839
Symbol
ENTX

Entera Bio Ltd. Stock price

$1.95
+0.09 4.84% 1M
-0.15 7.14% 6M
-0.17 8.02% YTD
+0.29 17.47% 1Y
+0.55 39.29% 3Y
+0.64 48.86% 5Y
-4.33 68.95% 10Y
-4.33 68.95% 20Y
Nasdaq, Closing price Mon, Aug 25 2025
+0.01 0.52%
ISIN
IL0011429839
Symbol
ENTX
Industry

Key metrics

Basic
Market capitalization
$89.0m
Enterprise Value
$78.2m
Net debt
positive
Cash
$10.9m
Shares outstanding
45.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
523.8 | 2,078.4
EV/Sales
459.9 | 1,824.9
EV/FCF
negative
P/B
5.2
Financial Health
Equity Ratio
86.1%
Return on Equity
-118.1%
ROCE
-59.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$170.0k | $42.8k
EBITDA
$-10.6m | -
EBIT
$-10.6m | $-29.0m
Net Income
$-10.6m | $-25.5m
Free Cash Flow
$-6.7m
Growth (TTM | estimate)
Revenue
183.3% | -76.2%
EBITDA
-63.1% | -
EBIT
-62.5% | -202.1%
Net Income
-62.6% | -167.3%
Free Cash Flow
8.7%
Margin (TTM | estimate)
Gross
0.0%
EBITDA
-6,356.6% | -
EBIT
-6,378.9%
Net
-6,386.8% | -59,517.9%
Free Cash Flow
-4,033.7%
More
EPS
$-0.2
FCF per Share
$-0.1
Short interest
0.1%
Employees
19
Rev per Employee
$10.0k
Show more

Is Entera Bio Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Entera Bio Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Entera Bio Ltd. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Entera Bio Ltd. forecast:

Buy
86%
Hold
14%

Financial data from Entera Bio Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.17 0.17
183% 183%
100%
- Direct Costs 0.17 0.17
240% 240%
100%
- -
-
-
- Selling and Administrative Expenses 5.27 5.27
71% 71%
3,100%
- Research and Development Expense 5.32 5.32
54% 54%
3,129%
-11 -11
63% 63%
-6,206%
- Depreciation and Amortization 0.04 0.04
20% 20%
24%
EBIT (Operating Income) EBIT -11 -11
62% 62%
-6,229%
Net Profit -11 -11
63% 63%
-6,235%

In millions USD.

Don't miss a Thing! We will send you all news about Entera Bio Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Entera Bio Ltd. Stock News

Positive
The Motley Fool
17 days ago
Entera Bio (ENTX 1.11%), a clinical-stage biotech specializing in oral delivery of protein and peptide drugs, released its earnings for the second quarter of fiscal 2025 on August 8, 2025. The most notable news was a better-than-expected GAAP earnings per share of $0.06, compared to Wall Street estimates for a GAAP loss of $(0.11).
Neutral
GlobeNewsWire
17 days ago
JERUSALEM, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended June 30, 2025.
Neutral
GlobeNewsWire
29 days ago
JERUSALEM, July 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response to a Type A meeting request, the U.S. Food and Drug Administration (FDA) agreed with the Company's proposal that the NDA marketing application filing for EB613 would be supported by a single multin...
More Entera Bio Ltd. News

Company Profile

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of orally delivered large molecule therapeutics. It develops an oral formulation of parathyroid hormone. The company was founded on June 1, 2010 and is headquartered in Jerusalem, Israel.

Head office Israel
CEO Miranda Toledano
Employees 19
Founded 2009
Website enterabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today